<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02619565</url>
  </required_header>
  <id_info>
    <org_study_id>AOM09236 - P081246</org_study_id>
    <nct_id>NCT02619565</nct_id>
  </id_info>
  <brief_title>Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes</brief_title>
  <acronym>MDS04</acronym>
  <official_title>Prognostic Value of Recurrent Mutations in a Prospective Cohort of Myelodysplasia and Secondary Acute Myeloid Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Cochin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at prospectively enrolling a cohort of 400 incident cases of myelodysplastic
      syndromes (MDS) at diagnosis, to evaluate the impact of recurrent mutations on overall
      survival and event-free survival, using next generation sequencing. Patients are affected by
      ineffective hematopoiesis and a propensity to leukemia in the elderly with a global incidence
      of 10/100,000/year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes (MDS) are a heterogeneous group of stem cell disorders
      characterized by ineffective hematopoiesis with dysplasia and a propensity to acute myeloid
      leukemia. Patients are affected in the elderly with a global incidence of 10/100,000/year.

      During the past 3 years, a significant progress has been made in the understanding of
      molecular pathogenesis through identification of mutations in epigenetic genes like TET2,
      ASXL1, EZH2, RUNX1, DNMT3A, IDH1/2, transcription factors, signalling molecules, cohesion and
      splicing regulators. Inactivating mutations targeting the hematopoietic stem cell may alter
      its gene expression pattern and could be an early mechanism of clonal selection. However, a
      single genetic alteration does not readily recapitulate the apoptotic and dysplastic
      phenotype. Several clones may co-exist, but their architecture is still unclear.

      This study aims at prospectively enrolling a cohort of 350 incident cases at diagnosis, to
      identify evaluate the impact of recurrent mutations on overall survival and event-free
      survival, using next generation sequencing.

      Considering the current knowledge, investigators propose to:

        -  perform whole exome sequencing to identify new mutations in a subset of 30 patients at
           diagnosis and in 10/30 samples at follow-up, and validate the recurrence of the new
           mutations in a training set.

        -  validate a high throughput technology for extensive genotyping to determine the
           mutational status of 54 target genes in the entire prospective cohort.

        -  analyze the frequency and impact on phenotype, OS and EFS of the most frequent mutations
           including SF3B1, SRSF2, ZRSR2, U2AF1, TET2, ASXL1, EZH2, IDH1/2, DNMT3A, NRAS, TP53, and
           RUNX1 and possibly of the newly discovered new mutations. Individual follow-up will be
           36 months.

      As ancillary studies, the evolution of mutation profiles after leukemic transformation in
      10/30 MDS tested by WES, or after evaluation of the response to treatments in 100 MDS
      included in clinical trials of the &quot;Groupe Francophone des Myélodysplasies&quot; will be analyzed.

      Understanding clonal architecture at diagnosis and after leukemic transformation is crucial
      for the knowledge of the pathophysiology of MDS. Better knowledge could help to adapt the
      therapeutic strategy. The study will help to delineate the pattern of genes which mutations
      with independent prognostic value modify the natural course of the disease. Then,
      investigators will apply for a grant to support a medico-economic evaluation of the molecular
      diagnosis in MDS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2010</start_date>
  <completion_date type="Actual">June 12, 2017</completion_date>
  <primary_completion_date type="Actual">June 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who survived event-free</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of surviving patients</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of mutations on event-free survival in myelodysplastic syndromes</measure>
    <time_frame>5 years</time_frame>
    <description>prevalence of TET2 mutation and other karyotypic abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medullary blast and Hemoglobin, platelet and neutrophil polynuclear</measure>
    <time_frame>5 years</time_frame>
    <description>to evaluate response to treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">349</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Blood samples if evolution of the disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood samples at Day 0 and also if there is an evolution of the disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood samples</intervention_name>
    <description>blood samples at Day 0 and also if there is an evolution of the disease</description>
    <arm_group_label>Blood samples if evolution of the disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Myelodysplastic syndromes, mixed myelodysplastic/myeloproliferative disorders or secondary
        acute myeloid leukemia at diagnosis:

          -  De novo MDS subtype according to the WHO classification: RCMD and RA with or without
             ring sideroblasts, RAEB 1, or MDS-U, RAEB 2, therapy-related MDS or sAML, MDS/MPD.

          -  IPSS

          -  Documented chromosome 5 and 7 abnormality (del(5q) or -5, del(7q) or -7) by FISH
             analysis, if possible AND

          -  ECOG performance status ≤ 2

          -  Age ≥ 18 years

          -  Life expectancy ≥ 3 months

          -  Adequate renal and liver function (transaminases serum levels ≤ 3N; calculated
             creatinine clearance &gt; 40 ml/min)

          -  Signed informed consent prior to start of any study-specific procedures

          -  Ability to participate to a clinical trial and adhere to study procedures

        Exclusion Criteria:

          -  Active serious infection not controlled by oral or intravenous antibiotics

          -  Treatment with any investigational antileukemic agent or chemotherapy at least 6 weeks
             prior to study entry and lack of full recovery from side effects due to prior therapy
             independent of when that therapy were given

          -  Rapidly progressive disease with compromised organ function judged to be
             life-threatening by the Investigator

          -  Pregnant or lactating female

          -  Known human immunodeficiency virus (HIV) infection

          -  Known active hepatitis B and/or C virus infection

          -  ECOG performance status &gt; 2

          -  Age &lt; 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michaela Fontenay, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance publique-Hôpitaux de Paris and Paris Descartes University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance publique-Hôpitaux de Paris, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.carpem.fr</url>
    <description>Cancer research for personalized medicine is a consortium dedicated to integrative research against cancer at the Assistance Publique-Hôpitaux de Paris</description>
  </link>
  <reference>
    <citation>Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069.</citation>
    <PMID>19474426</PMID>
  </reference>
  <reference>
    <citation>Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7.</citation>
    <PMID>19666869</PMID>
  </reference>
  <reference>
    <citation>Kosmider O, Gelsi-Boyer V, Ciudad M, Racoeur C, Jooste V, Vey N, Quesnel B, Fenaux P, Bastie JN, Beyne-Rauzy O, Stamatoulas A, Dreyfus F, Ifrah N, de Botton S, Vainchenker W, Bernard OA, Birnbaum D, Fontenay M, Solary E; Groupe Francophone des Myélodysplasies. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1.</citation>
    <PMID>19797729</PMID>
  </reference>
  <reference>
    <citation>Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood. 2010 Aug 19;116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20.</citation>
    <PMID>20489055</PMID>
  </reference>
  <reference>
    <citation>Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M; Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.</citation>
    <PMID>21494260</PMID>
  </reference>
  <reference>
    <citation>Kosmider O, Delabesse E, de Mas VM, Cornillet-Lefebvre P, Blanchet O, Delmer A, Recher C, Raynaud S, Bouscary D, Viguié F, Lacombe C, Bernard OA, Ifrah N, Dreyfus F, Fontenay M; GOELAMS Investigators. TET2 mutations in secondary acute myeloid leukemias: a French retrospective study. Haematologica. 2011 Jul;96(7):1059-63. doi: 10.3324/haematol.2011.040840. Epub 2011 Apr 20.</citation>
    <PMID>21508122</PMID>
  </reference>
  <reference>
    <citation>Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011 Jul 12;20(1):25-38. doi: 10.1016/j.ccr.2011.06.003. Epub 2011 Jun 30.</citation>
    <PMID>21723201</PMID>
  </reference>
  <reference>
    <citation>Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, Fontenay M. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010 May;24(5):1094-6. doi: 10.1038/leu.2010.52. Epub 2010 Apr 8.</citation>
    <PMID>20376084</PMID>
  </reference>
  <reference>
    <citation>Damm F, Thol F, Kosmider O, Kade S, Löffeld P, Dreyfus F, Stamatoullas-Bastard A, Tanguy-Schmidt A, Beyne-Rauzy O, de Botton S, Guerci-Bresler A, Göhring G, Schlegelberger B, Ganser A, Bernard OA, Fontenay M, Heuser M. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia. 2012 May;26(5):1137-40. doi: 10.1038/leu.2011.321. Epub 2011 Nov 8.</citation>
    <PMID>22064355</PMID>
  </reference>
  <reference>
    <citation>Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C, Della Valle V, Couronné L, Scourzic L, Chesnais V, Guerci-Bresler A, Slama B, Beyne-Rauzy O, Schmidt-Tanguy A, Stamatoullas-Bastard A, Dreyfus F, Prébet T, de Botton S, Vey N, Morgan MA, Cross NC, Preudhomme C, Birnbaum D, Bernard OA, Fontenay M; Groupe Francophone des Myélodysplasies. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012 Apr 5;119(14):3211-8. doi: 10.1182/blood-2011-12-400994. Epub 2012 Feb 17.</citation>
    <PMID>22343920</PMID>
  </reference>
  <reference>
    <citation>Frisan E, Vandekerckhove J, de Thonel A, Pierre-Eugène C, Sternberg A, Arlet JB, Floquet C, Gyan E, Kosmider O, Dreyfus F, Gabet AS, Courtois G, Vyas P, Ribeil JA, Zermati Y, Lacombe C, Mayeux P, Solary E, Garrido C, Hermine O, Fontenay M. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood. 2012 Feb 9;119(6):1532-42. doi: 10.1182/blood-2011-03-343475. Epub 2011 Dec 12.</citation>
    <PMID>22160620</PMID>
  </reference>
  <reference>
    <citation>Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y, Itzykson R, Sanada M, Shiraishi Y, Gelsi-Boyer V, Renneville A, Miyano S, Mori H, Shih LY, Park S, Dreyfus F, Guerci-Bresler A, Solary E, Rose C, Cheze S, Prébet T, Vey N, Legentil M, Duffourd Y, de Botton S, Preudhomme C, Birnbaum D, Bernard OA, Ogawa S, Fontenay M, Kosmider O. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013 Oct 31;122(18):3169-77. doi: 10.1182/blood-2012-11-469619. Epub 2013 Sep 18.</citation>
    <PMID>24047651</PMID>
  </reference>
  <reference>
    <citation>Damm F, Fontenay M, Bernard OA. Point mutations in myelodysplastic syndromes. N Engl J Med. 2011 Sep 22;365(12):1154-5; author reply 155. doi: 10.1056/NEJMc1108665.</citation>
    <PMID>21992131</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic syndromes</keyword>
  <keyword>mutations</keyword>
  <keyword>overall survival</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

